FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology, namely to new applications and methods of preventing or treating heart failure. Invention discloses the use of the ActRII receptor antibody for treating or preventing heart failure or for preparing a medicinal agent for treating or preventing heart failure. Anti-ActRII receptor antibody contains CDR1-3 of the heavy chain with SEQ ID NO: 9, 23, 37 respectively, and light chain CDR1-3 with SEQ ID NO: 51, 65, 79 respectively. Heart failure is caused by or associated with at least one of the following conditions: heart disease, ischemic heart disease, hypertension, diabetes, aging, arrhythmia, delivery cardiomyopathy, stress cardiomyopathy, toxic or infectious agents, genetic cardiomyopathy or idiopathic dilated cardiomyopathy.
EFFECT: inventions lead to improvement of cardiac function in various types of cardiac diseases.
8 cl, 8 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
